CY1114977T1 - Στοματικες μορφες δοσολογιας της βενδαμουστινης - Google Patents
Στοματικες μορφες δοσολογιας της βενδαμουστινηςInfo
- Publication number
- CY1114977T1 CY1114977T1 CY20141100174T CY141100174T CY1114977T1 CY 1114977 T1 CY1114977 T1 CY 1114977T1 CY 20141100174 T CY20141100174 T CY 20141100174T CY 141100174 T CY141100174 T CY 141100174T CY 1114977 T1 CY1114977 T1 CY 1114977T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutically acceptable
- vendamostein
- dosage
- oral forms
- bentamustine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Στην παρούσα εφεύρεση προβλέπεται στοματική φαρμακευτική σύνθεση, η οποία περιλαμβάνει βενδαμουστίνη ή φαρμακευτικά αποδεκτό εστέρα, άλας ή ουσία διάλυσης της ως δραστικό συστατικό, καθώς και φαρμακευτικά αποδεκτό έκδοχο, το οποίο είναι ένα φαρμακευτικά αποδεκτό μη ιοντικό τασιενεργό, το οποίο επιλέγεται από την ομάδα που αποτελείται από πολυαιθοξυλιωμένο καστορέλαιο ή παράγωγο του και μπλοκ συμπολυμερές οξειδίου αιθυλενίου και οξειδίου προπυλενίου.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08075915 | 2008-12-03 | ||
EP09796303.7A EP2367542B1 (en) | 2008-12-03 | 2009-12-03 | Oral dosage forms of bendamustine |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114977T1 true CY1114977T1 (el) | 2016-12-14 |
Family
ID=40588059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100174T CY1114977T1 (el) | 2008-12-03 | 2014-03-05 | Στοματικες μορφες δοσολογιας της βενδαμουστινης |
Country Status (25)
Country | Link |
---|---|
US (4) | US20120003305A1 (el) |
EP (1) | EP2367542B1 (el) |
JP (1) | JP5778037B2 (el) |
KR (1) | KR101688038B1 (el) |
CN (2) | CN105363037B (el) |
AU (1) | AU2009321745B2 (el) |
BR (1) | BRPI0922806B8 (el) |
CA (1) | CA2745525A1 (el) |
CO (1) | CO6400183A2 (el) |
CY (1) | CY1114977T1 (el) |
DK (1) | DK2367542T3 (el) |
EA (1) | EA020354B1 (el) |
ES (1) | ES2451540T3 (el) |
HR (1) | HRP20140204T1 (el) |
IL (1) | IL213270A (el) |
MX (1) | MX2011005643A (el) |
NZ (1) | NZ592970A (el) |
PL (1) | PL2367542T3 (el) |
PT (1) | PT2367542E (el) |
RS (1) | RS53201B (el) |
SI (1) | SI2367542T1 (el) |
SM (1) | SMT201400053B (el) |
UA (1) | UA102120C2 (el) |
WO (1) | WO2010063493A1 (el) |
ZA (1) | ZA201103791B (el) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3659B1 (ar) * | 2010-06-02 | 2020-08-27 | Astellas Deutschland Gmbh | أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية |
EP2575784B1 (en) * | 2010-06-02 | 2018-08-08 | Astellas Deutschland GmbH | Oral dosage forms of bendamustine |
CN102375044B (zh) * | 2010-08-18 | 2015-04-08 | 重庆华邦胜凯制药有限公司 | 一种盐酸苯达莫司汀中间体z6有关物质的分析方法 |
WO2013046223A1 (en) * | 2011-09-26 | 2013-04-04 | Fresenius Kabi Oncology Ltd. | An improved process for the preparation of bendamustine hydrochloride |
EP4218937A3 (en) * | 2011-10-31 | 2023-10-25 | F. Hoffmann-La Roche AG | Anti-il13 antibody formulations |
EP2641592A1 (en) | 2012-03-23 | 2013-09-25 | Salmon Pharma GmbH | Pharmaceutical formulation comprising bendamustine |
SI2656843T1 (sl) | 2012-04-26 | 2015-06-30 | Helmut Schickaneder | Estri bendamustina in povezane spojine ter njihova medicinska uporaba |
AU2013342015B2 (en) * | 2012-11-12 | 2016-11-24 | Ignyta, Inc. | Bendamustine derivatives and methods of using same |
EP2968153B1 (en) * | 2013-03-12 | 2018-05-02 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
JP2016153374A (ja) * | 2013-06-25 | 2016-08-25 | シンバイオ製薬株式会社 | 炎症性疾患を治療又は予防するための医薬組成物 |
CN105491886B (zh) | 2013-08-27 | 2019-01-29 | V·沃道里斯 | 苯达莫司汀医药组合物 |
AU2018346395A1 (en) | 2017-10-05 | 2020-04-30 | Mecox Curemed Co., Ltd. | Oral bendamustine formulations |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US132502A (en) * | 1872-10-22 | Improvement in machines for removing snow from railroads | ||
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US20030105141A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Finely self-emulsifiable pharmaceutical composition |
US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
CN101052396A (zh) * | 2004-11-05 | 2007-10-10 | 赛福伦公司 | 癌症治疗 |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
CN101119708B (zh) * | 2005-01-14 | 2014-12-24 | 赛福伦公司 | 苯达莫司汀冻干药物组合物 |
US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
CN101028249A (zh) * | 2007-04-12 | 2007-09-05 | 济南康泉医药科技有限公司 | 一种含新生血管抑制剂及烷化剂的抗癌组合物 |
CN101045058A (zh) * | 2007-04-28 | 2007-10-03 | 济南帅华医药科技有限公司 | 一种含烷化剂及激素类药物的抗癌组合物 |
CN101084876A (zh) * | 2007-07-11 | 2007-12-12 | 济南康泉医药科技有限公司 | 一种含苯达莫司汀的抗癌组合物 |
US20090130198A1 (en) * | 2007-11-21 | 2009-05-21 | Innopharmax Inc. | Pharmaceutical composition with enhanced bioavailability |
US8349353B2 (en) * | 2008-06-27 | 2013-01-08 | Otonomy, Inc. | Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders |
-
2009
- 2009-12-03 EA EA201190011A patent/EA020354B1/ru unknown
- 2009-12-03 RS RS20140111A patent/RS53201B/en unknown
- 2009-12-03 ES ES09796303.7T patent/ES2451540T3/es active Active
- 2009-12-03 DK DK09796303.7T patent/DK2367542T3/da active
- 2009-12-03 SI SI200930877T patent/SI2367542T1/sl unknown
- 2009-12-03 UA UAA201106235A patent/UA102120C2/ru unknown
- 2009-12-03 PT PT97963037T patent/PT2367542E/pt unknown
- 2009-12-03 WO PCT/EP2009/008857 patent/WO2010063493A1/en active Application Filing
- 2009-12-03 NZ NZ592970A patent/NZ592970A/xx unknown
- 2009-12-03 JP JP2011538906A patent/JP5778037B2/ja active Active
- 2009-12-03 CN CN201510849775.0A patent/CN105363037B/zh active Active
- 2009-12-03 AU AU2009321745A patent/AU2009321745B2/en active Active
- 2009-12-03 US US13/132,263 patent/US20120003305A1/en not_active Abandoned
- 2009-12-03 BR BRPI0922806A patent/BRPI0922806B8/pt active IP Right Grant
- 2009-12-03 PL PL09796303T patent/PL2367542T3/pl unknown
- 2009-12-03 MX MX2011005643A patent/MX2011005643A/es active IP Right Grant
- 2009-12-03 CA CA2745525A patent/CA2745525A1/en not_active Abandoned
- 2009-12-03 CN CN2009801547145A patent/CN102281871A/zh active Pending
- 2009-12-03 EP EP09796303.7A patent/EP2367542B1/en active Active
- 2009-12-03 KR KR1020117015292A patent/KR101688038B1/ko active IP Right Grant
-
2011
- 2011-05-24 ZA ZA2011/03791A patent/ZA201103791B/en unknown
- 2011-05-31 IL IL213270A patent/IL213270A/en active IP Right Grant
- 2011-06-28 CO CO11080792A patent/CO6400183A2/es not_active Application Discontinuation
-
2013
- 2013-07-01 US US13/932,785 patent/US20140018334A1/en not_active Abandoned
-
2014
- 2014-03-05 CY CY20141100174T patent/CY1114977T1/el unknown
- 2014-03-05 HR HRP20140204AT patent/HRP20140204T1/hr unknown
- 2014-04-22 SM SM201400053T patent/SMT201400053B/xx unknown
-
2015
- 2015-04-24 US US14/695,527 patent/US20150335588A1/en not_active Abandoned
-
2016
- 2016-06-06 US US15/174,467 patent/US10543196B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114977T1 (el) | Στοματικες μορφες δοσολογιας της βενδαμουστινης | |
CY1119177T1 (el) | Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτα και μεθοδοι χρησης αυτων | |
CY1123810T1 (el) | Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
CY1119248T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
CY1120796T1 (el) | Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων | |
CY1118232T1 (el) | Διαμορφωτες φαρμακοκινητικων ιδιοτητων θεραπευτικων παραγοντων | |
CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
CY1116150T1 (el) | Παραγωγα οξαδιαζολης και η χρηση τους ως ενισχυτων μεταβοτροπικου υποδοχεα γλουταμικου - 842 | |
CY1118541T1 (el) | D2 αποκλειστες, μεθοδοι συνθεσης και μεθοδοι χρησης | |
BR112012024796A2 (pt) | inibidores de integrase macrocíclicos | |
TW200745078A (en) | Isoindole-imide compounds and compositions comprising and methods of using the same | |
EA201390662A1 (ru) | Фармацевтическая композиция, содержащая дутастерид | |
ATE536172T1 (de) | Ezetimibzusammensetzungen | |
EA201070483A1 (ru) | Новые офтальмологические композиции | |
EA201300617A1 (ru) | β-ЛАКТАМОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ β-ЛАКТАМАЗЫ И ИХ ПРИМЕНЕНИЕ | |
CY1124907T1 (el) | Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα | |
EA201291104A1 (ru) | Пероральные лекарственные формы бендамустина | |
MX347928B (es) | Derivados de fenetilsulfona isoindolina y su uso. | |
EA201290229A1 (ru) | Производные спиролактама и их применение | |
AR064152A1 (es) | Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion. | |
WO2008004100A3 (en) | Therapeutic compounds | |
WO2008039894A3 (en) | Atorvastatin pharmaceutical compositions | |
CR20210086A (es) | Formulaciones de dendrímeros | |
WO2011128914A3 (en) | Extended release pharmaceutical compositions of pramipexole | |
CY1117266T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντι-καρκινικοι παραγοντες |